ARTICLE Recognizing and Diagnosing Abdominal Migraines Debbie M. Popovich, MSN, CPNP, Denise M. Schentrup, DNP, ARNP-BC, & Allison L. McAlhany, MSN, CPNP ABSTRACT Abdominal migraine affects 1% to 4% of children and is a variant of migraine headaches. Onset is seen most often between the ages of 7 to 12 years, with girls affected more often than boys. Presenting symptoms include acute incapacitating non-colicky periumbilical abdominal pain that lasts for 1 or more hours. Pallor, anorexia, nausea, vomiting, photophobia, or headache may be associated with the episodes, and a family history of migraine headaches often is noted. The diagnostic process begins with a thorough history and physical examination and often follows a series of exclusions or elimination of other organic causes. Limited research exists regarding treatment options, but they may include pharmacologic intervention and prevention based on lifestyle modifications. J Pediatr Health Care. (2010) 24, 372-377. KEY WORDS Abdominal migraine, migraine, abdominal pain, headache, periumbilical pain, cyclic vomiting syndrome Abdominal migraine (AM) affects as many as 1% to 4% of all children in the United States (Collins & Debbie M. Popovich, Assistant Professor, University of Florida College of Nursing, Gainesville, FL. Denise M. Schentrup, Clinical Assistant Professor, University of Florida College of Nursing, Gainesville, FL. Allison L. McAlhany, Clinical Assistant Professor, University of Florida College of Nursing, Gainesville, FL. Conflicts of interest: None to report. Correspondence: Debbie M. Popovich, MSN, CPNP, University of Florida College of Nursing, PO Box 100197, Gainesville, FL 32610; e-mail: [email protected]. 0891-5245/$36.00 Copyright Q 2010 by the National Association of Pediatric Nurse Practitioners. Published by Elsevier Inc. All rights reserved. doi:10.1016/j.pedhc.2009.11.003 372 Volume 24 Number 6 Thomas, 2007; Rasquin et al., 2006). However, it often is overlooked as children are tested by any number of specialists for a multitude of organic conditions before the correct diagnosis is made. To some extent, the inability of many children to adequately describe their pain experience may hinder efforts at diagnosis, and migraine experts, usually neurologists, do not often see children presenting with AMs (Russell, Abu-Arafeh, & Symon, 2002). Nurse practitioners and pediatricians are more familiar with this syndrome but may lack knowledge about recently published criteria to aid in diagnosing it. Diagnostic criteria for AM was added to the International Headache Society’s International Classification of Headache Disorders-II (ICHD-II) as recently as 2004 (Box 1) and to the Rome III Pediatric Criteria for Functional Gastrointestinal Disorders (FGIDs) in 2006 (Box 2) (Rasquin et al., 2006). The two criteria differ in the number of episodes required for diAM is characterized agnosis. The Rome III by acute, criteria suggest the diparoxysmal agnosis after two episodes, whereas the episodes of ICHD-II requires five abdominal pain episodes for a diagnofollowed by intense sis of AM. Fortunately, use of either of these periumbilical pain. criteria to aid in diagnosis may considerably shorten what has been a typically protracted evaluation process. In simplest terms, AM is characterized by acute, paroxysmal episodes of abdominal pain followed by intense periumbilical pain. Typically there is no accompanying headache with the abdominal symptoms. The condition is more prevalent in girls than in boys (3:2). The mean age of onset is 7 years, with a peak at 10 to 12 years of age for both sexes (Rasquin et al., 2006). Occasionally, it may persist into adulthood, although this is quite uncommon. Dignan and colleagues (2001) Journal of Pediatric Health Care BOX 1. Diagnostic criteria for abdominal migraine as established by the International Headache Society and reported by the International Classification of Headache Disorders II, 2004 Definition An idiopathic recurrent disorder occurring primarily in children and characterized by episodic midline abdominal pain manifesting in attacks normality between episode intensity and associated with vasomotor symptoms, nausea, and vomiting. Criteria A. At least five attacks fulfilling criteria B-D B. Attacks of abdominal pain lasting 1 to 72 hours C. Abdominal pain has all the following characteristics: 1. Midline location, periumbilical or poorly localized 2. Dull or ‘‘just sore’’ quality 3. Moderate to severe intensity D. During abdominal pain, at least 2 of the following: 1. Anorexia 2. Nausea 3. Vomiting 4. Pallor E. Not attributed to another disorder; history and physical examination findings do not suggest gastrointestinal or renal disease, or such disease has been ruled out by appropriate investigations found that AM did persist into the late teens in 38% of their 54 cases. SYMPTOMATOLOGY AM symptoms are characterized by acute episodic, midline periumbilical abdominal pain that is dull in nature, lasting for several hours to days, and associated with flushing, pallor, anorexia, nausea, vomiting, and photophobia (Lewis, 2009). Symptoms recur at least twice a year, and the child is typically pain free in between episodes. A family history of migraine headaches is common. In a prospective study, researchers reviewed 150 case histories of AM over a 10-year period. A family history of cephalic migraines in first-degree relatives was identified in 90% of cases (Bentley, Kehely, AlBayaty, & Michie, 1995). A clinical retrospective survey of 5848 pediatric ambulatory patients revealed that 65% of cases with AM/cyclical vomiting had a family history of migraine (Al-Twaijri & Shevell, 2002). In a 2005 study, Stickler (2005) also reported that mothers and grandmothers of patients with AM were twice as likely to experience migraines when compared with a control group with no migraine history. Brams introduced the term abdominal migraine nearly a century ago, in 1922. He believed the condition was under-diagnosed by gastroenterologists and neurologists. The onset of abdominal pain was described www.jpedhc.org BOX 2. Rome III diagnostic criteria* for abdominal migraine For a diagnosis of abdominal migraine, all of the following must apply: 1. Paroxysmal episodes of intense, acute periumbilical pain that lasts for 1 hour or more 2. Intervening periods of usual health lasting weeks to months 3. Pain interferes with normal activities 4. Pain is associated with two or more of the following: a. Anorexia b. Nausea c. Vomiting d. Headache e. Photophobia f. Pallor 5. No evidence of an inflammatory, anatomic, metabolic, or neoplastic process considered that explains the patient’s symptoms *Criteria fulfilled two or more times in the preceding 12 months. as abrupt, recurrent, and persistent for 3 to 4 days and ending just as abruptly. The interval between attacks of pain was symptom free (Brams, 1922). Dignan et al. (2001) thought it was common for pediatric abdominal pain to give way to migraine headaches. They tracked 54 children with AM into young adulthood and found that 70% were present or past sufferers of migraine headaches, compared with only 20% of matched control subjects. Other researchers suggest that AM, cyclic vomiting syndrome, and migraine headache comprise a continuum of a single disorder and that affected individuals often progress from one clinical symptom to another (Abu-Arafeh & Russell, 2002). Cyclic vomiting syndrome and AM have been used interchangeably, but there are significant differences to support their separation, mainly the presence or absence of migraine headache (Catto-Smith & Ranuh, 2003). The principle textbook on migraines, The Headaches, second edition (2000), devoted a chapter on migrainerelated syndromes in children, including AM. Because of widespread acceptance by health care providers of AM as a unique diagnostic entity, the Headache Classification Subcommittee of the International Headache Society (2004) included AM in the second edition of their classification within the group ‘‘Childhood periodic syndrome precursor of migraine’’ and coded it as 1.3.2. PATHOPHYSIOLOGY Several hypotheses have been investigated to determine the pathogenesis and pathophysiology of abdominal migraine pain. Factors include IgE-mediated diet-induced allergy, gut mucosal immune responses, phenol sulfotransferase enzyme M and P catabolism November/December 2010 373 of catecholamines and monoamines, and the permeability of the gut mucosal surface (Bentley et al., 1995). Weydert, Ball, and Davis (2003) discussed the relationship between the gut and the central nervous system (CNS). Derived from the same embryologic tissues, the enteric nervous system and CNS have direct effects on each other. These investigators proposed that stress increases CNS arousal, during which neuropeptides and neurotransmitters are released. This situation, in turn, leads to dysregulation of the gastrointestinal system. While the consistent symptom is episodic abdominal pain with clear-cut symptom-free intervals, the pathophysiology of pain is beyond the scope of this discussion. CASE STUDY A 15-year-old girl presented as a new patient with intermittent episodes of abdominal pain and vomiting since infancy, occurring up to four times per month. Symptoms included non-radiating abdominal pain and vomiting. Pain was not relieved with bowel movements or position change and continued for 24 hours. There were no identified triggers, and headache was denied. No other associated symptoms were reported. Previous evaluations included a complete blood cell count with differential, a complete metabolic panel , erythrocyte sedimentation rate, urinalysis, urine culture, serum human chorionic gonadotropin, thyroid studies, serum amino and urine organic acids, lipase, amylase, toxicology, and hemoglobin electrophoresis; all results were normal. Findings of an abdominal x-ray, abdominal/renal ultrasound, and upper gastrointestinal study with small bowel follow-through also were normal. Past medications included Zofran (ondansetron) and Phenergan (promethazine) without improvement. Fioricet, prescribed for the mother’s migraine headaches, was marginally effective. Nonpharmacologic treatment failures included dietary restrictions and stress reduction strategies. There is a reported history of migraine headache in the patient’s mother. Her examination was within normal limits in all systems. The child’s history and symptoms met ICHD-II criteria for AM. Successful treatment included administration of prophylactic tricyclic antidepressants. Follow-up evaluation revealed a marked reduction in episodes of abdominal pain. other causes of intermittent severe abdominal pain should be considered and systematically excluded. In contrast to acute and chronic abdominal pain, an explanation for recurrent abdominal pain is seldom found (Russell et al., 2002). It is estimated that Ultimately, only 5% to 10% of children diagnosis is with recurrent abdominal based on the pain have an underlying organic process that conmedical history, tributes to their pain (Weyabsence of dert et al., 2003). abnormality, and The health care provider must conduct a thorough fulfillment of physical examination and recognized obtain the health history criteria. of the child and his or her family. Collins and Thomas (2007) identified ‘‘red flag’’ signs and symptoms suggestive of organic diseases (Box 3), which suggest a higher likelihood of pathology requiring subspecialty referral and possible endoscopy. Catto-Smith and Ranuh (2003) recommended initial diagnostic studies (Box 4), and Diamond (2002) advocated for the consistent inclusion of appendicitis, volvulus, bowel malrotation, and posterior fossa tumors as part of the AM differential diagnosis. Ultimately, diagnosis is based on the medical history, absence of abnormality, and fulfillment of recognized criteria. MANAGEMENT Treatment and management of AM in children should be kept simple and are determined by the severity, frequency, and impact on the daily life of the child and BOX 3. Red flags suggesting further workup needed Unexplained subjective and objective findings including: d d d d d DIAGNOSIS When accompanied by a history of migraine headaches, the diagnosis of AM is straightforward (Collins & Thomas, 2007). AM is excluded, however, if any of the following are present: mild symptoms not interfering with daily activities; burning pain; non-midline abdominal pain; symptoms consistent with food allergy or other gastrointestinal disease; attacks lasting less than 1 hour; or persistence of symptoms between attacks (Lewis, Yonker, Winner, & Sowell, 2005). In all other cases, the diagnosis should remain presumptive, and 374 Volume 24 Number 6 d d d d d d d d d d Change in growth patterns includes height and weight Recurrent unexplained fevers Pain radiating to the back Bilious emesis Visible or occult blood in stool Chronic diarrhea (lasting >2 weeks and >20 mL/kg per day) Mouth ulcers Dysphagia Rashes with no identifiable cause Nighttime symptoms Arthritis Anemia Pale mucus membranes Delayed puberty Family history of inflammatory bowel disease Journal of Pediatric Health Care BOX 4. Initial diagnostic studies for consideration in children presenting with possible cyclic vomiting syndrome or abdominal migraine Blood studies d Hemoglobin, white count and differential d C-reactive protein d Electrolytes, creatinine and glucose d Liver function tests d Pancreatic enzymes d Pregnancy test Urine and stool studies d Urinalysis with microscopy and culture d Stool occult blood and microscopy Radiologic studies d Ultrasound of liver, gall bladder, biliary tract, pancreas, adrenal glands, and kidneys d Upper GI series d Magnetic resonance imaging or CT of brain Endoscopy d Esophagogastroduodenoscopy d Colonoscopy with ileoscopy (to exclude Crohn’s disease) Data from Pareek, Fleisher, & Abell, 2007. his or her family. According to recently published findings, the Franklin (1952) approach remains the cornerstone for management of AM: explanation, reassurance, search for possible triggers, and behavioral approaches (Russell, Symon, & Abu-Arafeh, 2007). Severe and protracted episodes of emesis, however, may warrant hospitalization and require intravenous fluids to counteract dehydration. NONPHARMACOLOGIC THERAPY Because minimal data are available regarding AM treatment, Lewis et al. (2005), Russell et al. (2002), and Diamond (2002) offered experiential and anecdotal rather than evidence-based nonpharmacologic recommendations, beginning with family education and avoidance of triggers. Suggested strategies for identified triggers include the following: d d d d d d Effective coping strategies to prevent and relieve stress Bedtime fiber snack to prolong the glycemic effect and avoid hypoglycemia and related acute morning attacks Frequent travel stops to prevent motion sickness Routine bedtime to prevent altered sleep patterns Use of a hat or sunglasses to eliminate glare and diminish bright lights Use of a diet low in amines, which includes many food that begin with the letter ‘‘C’’—that is, chocolate, cocoa, citrus, caffeine (cola, coffee, tea), cheese, and www.jpedhc.org d colorings (in sweets and chewing gum); additives such as monosodium glutamate (MSG); currants, raisins, and black grapes; and flavorings such as those in snacks like potato chips Identifying specific foods by restricting the diet and gradually re-introducing foods over a 2-week period PHARMACOLOGIC THERAPY Abnormal concentrations of vasoactive amines, such as noradrenaline and serotonin, typically are found in adults who have migraine headaches. Anti-migraine drugs are intended to prevent the painful events by interfering with the biochemical pathways. There are no studies evaluating similar biochemical imbalances in children with AM; however, pharmacologic management in the treatment of migraine headaches has proved to be effective in treatment of AM (Tan, Sahami, Peebles, & Shaw, 2006). Lewis et al. (2005) also suggested that treatment guidelines for migraine headaches may prove to be efficacious for the management of AM. In the practice guidelines published in 2004, Lewis et al. summarized data from numerous studies that focused on abortive treatment, specifically nasal sumatriptan, as well as preventive treatment of migraines in children, noting that similar treatment has been proven effective in persons with AM. Catto-Smith and Ranuh (2003) found tricyclic antidepressants to be effective prophylactic agents, and Lewis, Winner, Hershey, and Wasiewski (2007) also found propranolol (2 to 4 mg/kg/day) and cyproheptadine (0.25 to 1.5 mg/kg) to be effective. Lewis (2009) also noted that cyproheptadine at a starting dose of 2 to 4 mg at bedtime is a simple, effective, and safe strategy for children younger than 10 years who are not overweight. Lewis (2007) incorporates the work of a number of other researchers (Ahonen, Hamalainen, Rantala, & Hoppu, 2004; Major, Grubisa, & Thie, 2003; Uberall, 2001; Winner et al., 2000) when he states the following: The agents studied most rigorously for the acute treatment of migraine [headache] are ibuprofen (10 mg/kg/dose), acetaminophen (10-15 mg/kg/ dose) for children under 12 years of age, and sumatriptan nasal spray, all of which have shown safety and efficacy in controlled trials (2007, p. 50). Although none of the selective serotonin receptor agonists or triptans have been approved by the Food and Drug Administration for use with children and adolescents, multiple studies have demonstrated their safety for children’s use (Major et al., 2003). Thus far, only sumatriptan in the nasal spray form, 5 and 20 mg, has demonstrated efficacy in adolescents (Ahonen et al., 2004; Lewis et al., 2004; Uberall, 2001; Winner et al., 2000). In their review of the literature for pediatric migraines, Shah and Kalra (2009) observed that oral November/December 2010 375 formulations of selective serotonin receptor agonists were not beneficial in children. Zolmitriptan nasal spray (2.5 to 5 mg), demonstrated efficacy when evaluated in 12-to 17-year-old children (Lewis et al., 2007). Lewis and colleagues’ practice parameters (2004) addressed the limitations of pharmacologic agents, reporting inconclusive data regarding preventive treatment of migraine headaches. They concluded that further research is warranted before specific pharmacologic agents can be suggested. (An up-to-date reference list for AM is available online at the Web site for the Cyclic Vomiting Syndrome Association: www.cvsaonline.org). NURSING PRACTICE IMPLICATIONS Initial consideration of the diagnosis of AM is warranted if a child presents with intermittent severe abdominal pain without an identifiable cause. Symptom-free periods between episodes are essential to the diagnosis. A thorough history and physical examination is essential to rule out any physical causes of pain. The diagnosis should be made after other organic causes are ruled out. Initial episodes may mimic appendicitis or obstruction, and often an ab.use of the dominal scan is needed Rome III and to rule out acute proICHD-II criteria to cesses. The provider should encourage the aid in diagnosis caregiver to document may the frequency of epiconsiderably sodes, precipitating factors, and treatment shorten what has interventions. A symptom been a typically diary can identify triggers protracted and effective treatment strategies. Pharmacologic evaluation and non-pharmacologic process. measures should be attempted, and caregivers should be educated about the potential adverse effects of pharmacologic treatment. The goal of therapy is to abort episodes quickly to prevent interference with daily activities. Referrals to neurology and psychology specialists may be necessary for alternative treatments such as biofeedback if interventions are not successful. CONCLUSION AM, along with organic causes, must be considered in any child presenting with severe episodic abdominal pain, with or without headache. A thorough history and physical is essential for making the diagnosis, and use of the Rome III and ICHD-II criteria to aid in diagnosis may considerably shorten what has been a typically protracted evaluation process. Caregiver education about management of symptoms is also essential, and treatment should be individualized, because patient 376 Volume 24 Number 6 responses to treatment will vary. Pharmacologic treatment is currently limited but has been implemented in children who do not respond to nonpharmacologic therapy and whose symptoms have a negative impact on daily activities. The overall goal of treatment is to limit occurrence of episodes and thus improve quality of life for children and adolescents who have this disorder. REFERENCES Abu-Arafeh, I., & Russell, G. (2002). Childhood headache. Cambridge, MA: Cambridge University Press. Ahonen, K., Hamalainen, M. L., Rantala, H., & Hoppu, K. (2004). Nasal sumatriptan is effective in the treatment of migraine attacks in children. Neurology, 62, 883-887. Al-Twaijri, W. A., & Shevell, M. I. (2002). Pediatric migraine equivalents: Occurrence and clinical features in practice. Pediatric Neurology, 26(5), 365-368. Bentley, D., Kehely, A., Al-Bayaty, M., & Michie, C. A. (1995). Abdominal migraine as a cause of vomiting in children: A clinician’s view. Journal of Pediatric Gastroenterology and Nutrition, 21(Suppl. 1), S49-S51. Brams, W. A. (1922). Abdominal migraine. Journal of the American Medical Association, 78, 26-27. Catto-Smith, A. G., & Ranuh, R. (2003). Abdominal migraine and cyclical vomiting. Seminars in Pediatric Surgery, 12(4), 254258. Collins, B. S., & Thomas, D. W. (2007). Chronic abdominal pain. Pediatrics in Review, 28(9), 323-331. Diamond, S. (2002). An approach to the patient with abdominal migraine. (Headache of the month). Consultant, 42(10), 1314-1319. Dignan, F., Abu-Arafeh, I., & Russell, G. (2001). The prognosis of childhood abdominal migraine. Archives of Disease in Childhood, 84(4), 415-418. Franklin, A. W. (1952). Periodic disorders of children. Lancet, ii, 12671270. Headache Classification Subcommittee of the International Headache Society. (2004). Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. (2nd ed.) Cephalalgia, 24(Suppl. 1), 1–160. Lewis, D., Ashwal, S., Hershey, A., Hirtz, D., Yonker, M., & Silberstein, S. (2004). Practice parameters: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology, 63, 2215-2224. Lewis, D. W., Yonker, M., Winner, P., & Sowell, M. (2005). The treatment of pediatric migraine. Pediatric Annals, 34(6), 448-460. Lewis, D. W. (2007). Pediatric migraine. Pediatrics in Review, 28(2), 43-53. Lewis, D. W. (2009). Pediatric migraine. Neurologic Clinics, 27(2), 481-501. Major, P., Grubisa, H., & Thie, N. (2003). Triptans for the treatment of acute pediatric migraine: A systematic literature review. Pediatric Neurology, 29, 425-429. Pareek, N., Fleisher, D., & Abell, T. (2007). Cyclic vomiting syndrome: what a gastroenterologist needs to know. American Journal of Gastroenterology, 102(12), 2832-2840. Rasquin, A., Di Lorenzo, C., Forbes, D., Guiraldes, E., Hyams, J. S., Staiano, A., & Walker, L. S. (2006). Childhood functional gastrointestinal disorders: Child/adolescent. Gastroenterology, 130(5), 1527-1537. Russell, G., Abu-Arafeh, I., & Symon, D. N. K. (2002). Abdominal migraine: Evidence for existence and treatment options. Pediatric Drugs, 4(1), 1-8. Journal of Pediatric Health Care Russell, G., Symon, D. N. K., & Abu-Arafeh, I. (2007). The child with recurrent abdominal pain: Is it abdominal migraine? British Journal of Hospital Medicine, 68(7), M110-M113. Shah, U. H., & Kalra, V. (2009). Pediatric migraine. International Journal of Pediatrics, 2009, 1-7. Stickler, G. B. (2005). Relationship between cyclic vomiting syndrome and migraine. Clinical Pediatrics, 44(6), 505-508. Tan, V., Sahami, A. R., Peebles, R., & Shaw, R. J. (2006). Abdominal migraine and treatment with intravenous valproic acid. Psychosomatics, 47(4), 353-355. Uberall, M. (2001). Sumatriptan in paediatric and adolescent migraine. Cephalalgia, 24(Suppl 1), 210-224. Weydert, J. A., Ball, T. M., & Davis, M. F. (2003). Systematic review of treatments for recurrent abdominal pain. Pediatrics, 111(1), e1-e11. Winner, P., Rothner, A. D., Saper, J., Nett, R., Asgharnejad, M., & Laurenza, R. A. (2000). A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics, 105(5), 989-997. WANTED: CASE STUDIES The JPHC is seeking case studies in Primary Care and Acute & Specialty Care that you would like to share with the readers. Please contact the appropriate editor with your name, address (including email), and topic. A template for you to follow along with editorial support makes this easy, fun, and professionally rewarding. Manuscripts can be submitted online at http://ees.elsevier.com/jphc. CONTACT INFORMATION: Primary Care Editors Jo Ann Serota, MS, RN, CPNP, [email protected] Corresponding Editor Beverly P. Giordano, MS, RN, CPNP, [email protected] Donna Hallas, PhD, PNP-BC, CPNP, [email protected] Acute & Specialty Care Editors Andrea Kline, MS, RN, CPNP-PC/AC, CCRN, FCCM, [email protected] Corresponding Editor Terea Giannetta, MSN, RN, CPNP, [email protected] Karin Reuter-Rice, PhD, CPNP, [email protected] www.jpedhc.org November/December 2010 377
© Copyright 2024